UNSPSC 51452203: Ftalofyne or phthalofyne

This classification denotes an antihelminthic agent with the molecular formula C14H14O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TA9XO4D05J, chemically known as 1,2-benzenedicarboxylic acid, mono (1-ethyl-1-methyl-2-propynyl) ester, sodium salt but generally known as ftalofyne, which bears US NIH Compound Identifier 8573. European Medicines Agency schedules Ftalofyne in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07819MIG.

UNSPSC 51452203 Ftalofyne or phthalofyne is a Commodity code that does not reflect the actual scope of recent state and local procurement activity tagged under it. The code nominally describes a specialized chemical compound, yet the four most recent opportunities posted under this code involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic pharmaceuticals and over-the-counter products — none of which align with the code's stated chemical focus. This mismatch suggests either a systematic miscoding issue in the state and local procurement systems tagging these opportunities or a substantial divergence between the UNSPSC taxonomy label and actual purchasing intent at the issuing agencies.

The recent opportunities span issuing bodies including a Florida county health department (Seminole County), a state health and human services commission (Texas HHS Commission), a city fire department (City of Tampa), and a multistate cooperative purchasing alliance (Minnesota MMCAP). Geographic activity concentrates in Florida, Texas, Minnesota, and Oregon, with the most concrete procurement signals coming from Seminole County's IFB 60459723LAS (naloxone and drug deactivation systems, due July 26, 2023), the City of Tampa's bid 26-P-00145 for emergency medical supplies (estimated $700,000.00, due March 13, 2026), and MMCAP's RFP S1070000015802 for generic pharmaceuticals and OTC products (due March 26, 2026). Given the fundamental disconnect between the code's chemical nomenclature and the pharmaceutical, medical supplies, and health services procurement appearing under it, the code shows little meaningful recent activity in its stated commodity scope and should not be relied upon for targeting pharmaceutical or medical supply opportunities.